Salvage Treatment for Invasive Aspergillosis and Mucormycosis: Challenges, Recommendations and Future Considerations

References

• Egger M, Hoenigl M, Thompson GR 3rd, Carvalho A, Jenks JD. Let’s talk about sex characteristics - as a risk factor for invasive fungal diseases. Mycoses. 2022;65:599–612. doi:10.1111/myc.13449
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Salmanton-García J, Walsh TJ, et al. Global guideline for the diagnosis and management of rare mould infections: an initiative of the European confederation of medical mycology in cooperation with the international society for human and animal mycology and the American society for microbiology. Lancet Infect Dis. 2021;2021:1.
   Google Scholar
• Hoenigl M, Gangneux JP, Segal E, et al. Global guidelines and initiatives from the European confederation of medical mycology to improve patient care and research worldwide: new leadership is about working together. Mycoses. 20182018:5.
   Google Scholar
• Jenks JD, Aneke CI, Al-Obaidi MM, et al. Race and ethnicity: risk factors for fungal infections? PLoS Pathog. 2023;19(1):e1011025. doi:10.1371/journal.ppat.1011025
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Seidel D, Carvalho A, et al. The emergence of COVID-19 associated mucormycosis: a review of cases from 18 countries. Lancet Microb. 2022;3:e543–e552. doi:10.1016/S2666-5247(21)00237-8
   PubMedGoogle Scholar
• Cornely OA, Alastruey-Izquierdo A, Arenz D, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the Mycoses study group education and research consortium. Lancet Infect Dis. 2019;19:e405–e421. doi:10.1016/S1473-3099(19)30312-3
   PubMed Web of Science ®Google Scholar
• Salmanton-García J, Sprute R, Stemler J, et al. COVID-19-associated pulmonary aspergillosis, march-august 2020. Emerg Infect Dis. 2021;27(4):1077–1086. doi:10.3201/eid2704.204895
   PubMed Web of Science ®Google Scholar
• Arastehfar A, Carvalho A, Houbraken J, et al. Aspergillus fumigatus and aspergillosis: from basics to clinics. Stud Mycol. 2021;100:100115. doi:10.1016/j.simyco.2021.100115
   PubMed Web of Science ®Google Scholar
• Prattes J, Wauters J, Giacobbe DR, et al. Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients- a multinational observational study by the European confederation of medical mycology. Clin Microbiol Infect. 2021;28:580–587. doi:10.1016/j.cmi.2021.08.014
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Seidel D, Sprute R, et al. COVID-19-associated fungal infections. Nat Microbiol. 2022;7(8):1127–1140. doi:10.1038/s41564-022-01172-2
   PubMed Web of Science ®Google Scholar
• Reischies F, Hoenigl M. The role of surgical debridement in different clinical manifestations of invasive aspergillosis. Mycoses. 2014;57(Suppl 2):1–14. doi:10.1111/myc.12224
   PubMed Web of Science ®Google Scholar
• Jenks JD, Cornely OA, Chen SC, Thompson GR 3rd, Hoenigl M. Breakthrough invasive fungal infections: who is at risk? Mycoses. 2020;63:1021–1032. doi:10.1111/myc.13148
   PubMed Web of Science ®Google Scholar
• Cornely OA, Hoenigl M, Lass-Florl C, et al. Defining breakthrough invasive fungal infection-position paper of the mycoses study group education and research consortium and the European confederation of medical mycology. Mycoses. 2019;62(9):716–729. doi:10.1111/myc.12960
   PubMed Web of Science ®Google Scholar
• Jenks JD, Gangneux JP, Schwartz IS, et al. Diagnosis of breakthrough fungal infections in the clinical mycology laboratory: an ECMM consensus statement. J Fungi. 2020;6(4):216. doi:10.3390/jof6040216
   Web of Science ®Google Scholar
• Cornely OA, Bohme A, Schmitt-Hoffmann A, Ullmann AJ. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a Phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59(4):2078–2085. doi:10.1128/AAC.04569-14
   PubMed Web of Science ®Google Scholar
• Kriegl L, Hatzl S, Zurl C, et al. Isavuconazole plasma concentrations in critically ill patients during extracorporeal membrane oxygenation. J Antimicrob Chemother. 2022;77(9):2500–2505. doi:10.1093/jac/dkac196
   PubMed Web of Science ®Google Scholar
• Lenczuk D, Zinke-Cerwenka W, Greinix H, et al. Antifungal prophylaxis with posaconazole delayed-release tablet and oral suspension in a real-life setting: plasma levels, efficacy and tolerability. Antimicrob Agents Chemother. 2018;62. doi:10.1128/AAC.02655-17
   PubMed Web of Science ®Google Scholar
• Prattes J, Duettmann W, Hoenigl M. Posaconazole plasma concentrations on days three to five predict steady-state levels. Antimicrob Agents Chemother. 2016;60(9):5595–5599. doi:10.1128/AAC.00389-16
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Duettmann W, Raggam RB, et al. Potential factors for inadequate voriconazole plasma concentrations in intensive care unit patients and patients with hematological malignancies. Antimicrob Agents Chemother. 2013;57(7):3262–3267. doi:10.1128/AAC.00251-13
   PubMed Web of Science ®Google Scholar
• Zurl C, Waller M, Schwameis F, et al. Isavuconazole treatment in a mixed patient cohort with invasive fungal infections: outcome, tolerability and clinical implications of isavuconazole plasma concentrations. J Fungi. 2020;6(2):90. doi:10.3390/jof6020090
   Web of Science ®Google Scholar
• Hoenigl M, Duettmann W, Raggam RB, et al. Impact of structured personal on-site patient education on low posaconazole plasma concentrations in patients with haematological malignancies. Int J Antimicrob Agents. 2014;44(2):140–144. doi:10.1016/j.ijantimicag.2014.03.013
   PubMed Web of Science ®Google Scholar
• Ullmann A, Aguado JM, Arikan S, et al. Executive summary of the 2017 ESCMID-ECMM guideline for the diagnosis and management of aspergillus disease. Clin Microb Infect. 20182018:37.
   Google Scholar
• Jenks JD, Seidel D, Cornely OA, et al. Voriconazole plus terbinafine combination antifungal therapy for invasive Lomentospora prolificans infections: analysis of 41 patients from the FungiScope® registry 2008–2019. Clin Microb Infect. 2020;26:S1198-743X(20)30037–9. doi:10.1016/j.cmi.2020.01.012
   Google Scholar
• Hoenigl M, Sprute R, Egger M, et al. The antifungal pipeline: fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin. Drugs. 2021;2021:1–27.
   Google Scholar
• Herbrecht R. Posaconazole: a potent, extended-spectrum triazole anti-fungal for the treatment of serious fungal infections. Int J Clin Pract. 2004;58(6):612–624. doi:10.1111/j.1368-5031.2004.00167.x
   PubMed Web of Science ®Google Scholar
• Wexler D, Courtney R, Richards W, Banfield C, Lim J, Laughlin M. Effect of posaconazole on cytochrome P450 enzymes: a randomized, open-label, two-way crossover study. Eur J Pharm Sci. 2004;21(5):645–653. doi:10.1016/j.ejps.2004.01.005
   PubMed Web of Science ®Google Scholar
• Brajtburg J, Bolard J. Carrier effects on biological activity of amphotericin B. Clin Microbiol Rev. 1996;9(4):512–531. doi:10.1128/CMR.9.4.512
   PubMed Web of Science ®Google Scholar
• Bellmann R, Egger P, Wiedermann CJ. Differences in pharmacokinetics of amphotericin B lipid formulations despite clinical equivalence. Clin Infect Dis. 2003;36(11):1500–1501. doi:10.1086/374876
   PubMed Web of Science ®Google Scholar
• Bellmann R, Smuszkiewicz P. Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients. Infection. 2017;45(6):737–779.
   PubMed Web of Science ®Google Scholar
• Stone NR, Bicanic T, Salim R, Hope W. Liposomal amphotericin B (AmBisome((R))): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions. Drugs. 2016;76(4):485–500. doi:10.1007/s40265-016-0538-7
   PubMed Web of Science ®Google Scholar
• Hoenigl M, Krause R. Antifungal therapy of aspergillosis of the central nervous system and aspergillus endophthalmitis. Curr Pharm Des. 2013;19(20):3648–3668. doi:10.2174/13816128113199990342
   PubMed Web of Science ®Google Scholar
• Bellmann R, Egger P, Gritsch W, et al. Amphotericin B lipid formulations in critically ill patients on continuous veno-venous haemofiltration. J Antimicrob Chemother. 2003;51(3):671–681. doi:10.1093/jac/dkg139
   PubMed Web of Science ®Google Scholar
• Christiansen KJ, Bernard EM, Gold JW, Armstrong D. Distribution and activity of amphotericin B in humans. J Infect Dis. 1985;152(5):1037–1043. doi:10.1093/infdis/152.5.1037
   PubMed Web of Science ®Google Scholar
• Collette N, van der Auwera P, Lopez AP, Heymans C, Meunier F. Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate. Antimicrob Agents Chemother. 1989;33(3):362–368. doi:10.1128/AAC.33.3.362
   PubMed Web of Science ®Google Scholar
• Weiler S, Falkensammer G, Hammerer-Lercher A, et al. Pulmonary epithelial lining fluid concentrations after use of systemic amphotericin B lipid formulations. Antimicrob Agents Chemother. 2009;53(11):4934–4937. doi:10.1128/AAC.00796-09
   PubMed Web of Science ®Google Scholar
• Weiler S, Bellmann-Weiler R, Joannidis M, Bellmann R. Penetration of amphotericin B lipid formulations into pleural effusion. Antimicrob Agents Chemother. 2007;51(11):4211–4213. doi:10.1128/AAC.01087-07
   PubMed Web of Science ®Google Scholar
• van der Voort PH, Boerma EC, Yska JP. Serum and intraperitoneal levels of amphotericin B and flucytosine during intravenous treatment of critically ill patients with Candida peritonitis. J Antimicrob Chemother. 2007;59(5):952–956. doi:10.1093/jac/dkm074
   PubMed Web of Science ®Google Scholar
• Weiler S, Bellmann-Weiler R, Dunzendorfer S, Joannidis M, Bellmann R. Levels of amphotericin B lipid formulations in ascites. J Antimicrob Chemother. 2008;62(5):1163–1164. doi:10.1093/jac/dkn306
   PubMed Web of Science ®Google Scholar
• Vogelsinger H, Weiler S, Djanani A, et al. Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion. J Antimicrob Chemother. 2006;57(6):1153–1160. doi:10.1093/jac/dkl141
   PubMed Web of Science ®Google Scholar
• Patterson TF, Thompson GR 3rd, Denning DW, et al. Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the infectious diseases Society of America. Clin Infect Dis. 2016;63(4):e1–e60. doi:10.1093/cid/ciw326
   PubMed Web of Science ®Google Scholar
• Cornely OA, Arikan-Akdagli S, Dannaoui E, et al. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of mucormycosis 2013. Clin Microbiol Infect. 2014;20(Suppl 3):5–26. doi:10.1111/1469-0691.12371
   PubMed Web of Science ®Google Scholar
• Fleming RV, Kantarjian HM, Husni R, et al. Comparison of Amphotericin B Lipid Complex (ABLC) vs. AmBisome in the treatment of suspected or documented fungal infections in patients with leukemia. Leuk Lymphoma. 2001;40(5–6):511–520. doi:10.3109/10428190109097650
   PubMed Web of Science ®Google Scholar
• Wingard JR, White MH, Anaissie E, Raffalli J, Goodman J, Arrieta A. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC collaborative study group. Clin Infect Dis. 2000;31(5):1155–1163. doi:10.1086/317451
   PubMed Web of Science ®Google Scholar
• Chen SC, Slavin MA, Sorrell TC. Echinocandin antifungal drugs in fungal infections: a comparison. Drugs. 2011;71(1):11–41. doi:10.2165/11585270-000000000-00000
   PubMed Web of Science ®Google Scholar
• Cappelletty D, Eiselstein-McKitrick K. The echinocandins. Pharmacotherapy. 2007;27(3):369–388. doi:10.1592/phco.27.3.369
   PubMed Web of Science ®Google Scholar
• Denning DW. Echinocandin antifungal drugs. Lancet. 2003;362(9390):1142–1151. doi:10.1016/S0140-6736(03)14472-8
   PubMed Web of Science ®Google Scholar
• European Medicines Agency, Ecalta. EPAR-product information; 2014. Available from: http://www.ema.europa.eu. Accessed March 23, 2023.
   Google Scholar
• European Medicines Agency, Mycamine. EPAR-product information; 2011. Available from: http://www.ema.europa.eu. Accessed March 23, 2023.
   Google Scholar
• European Medicines Agency, Cancidas. EPAR-product information; 2016. Available from: http://www.ema.europa.eu. Accessed March 23, 2023.
   Google Scholar
• Maertens J, Raad I, Petrikkos G, et al. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy. Clin Infect Dis. 2004;39(11):1563–1571. doi:10.1086/423381
   PubMed Web of Science ®Google Scholar
• Viscoli C, Herbrecht R, Akan H, et al. An EORTC phase II study of caspofungin as first-line therapy of invasive aspergillosis in haematological patients. J Antimicrob Chemother. 2009;64(6):1274–1281. doi:10.1093/jac/dkp355
   PubMed Web of Science ®Google Scholar
• Herbrecht R, Maertens J, Baila L, et al. Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European organisation for research and treatment of cancer study. Bone Marrow Transplant. 2010;45(7):1227–1233. doi:10.1038/bmt.2009.334
   PubMed Web of Science ®Google Scholar
• Mora-Duarte J, Betts R, Rotstein C, et al. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347(25):2020–2029. doi:10.1056/NEJMoa021585
   PubMed Web of Science ®Google Scholar
• Lempers VJ, van den Heuvel JJ, Russel FG, et al. Inhibitory potential of antifungal drugs on ATP-binding cassette transporters P-glycoprotein, MRP1 to MRP5, BCRP, and BSEP. Antimicrob Agents Chemother. 2016;60(6):3372–3379. doi:10.1128/AAC.02931-15
   PubMed Web of Science ®Google Scholar
• Marx J, Reinstadler V, Gasperetti T, et al. Human tissue distribution of caspofungin. Int J Antimicrob Agents. 2022;59(4):106553. doi:10.1016/j.ijantimicag.2022.106553
   PubMed Web of Science ®Google Scholar
• Spitzer M, Robbins N, Wright GD. Combinatorial strategies for combating invasive fungal infections. Virulence. 2016;2016:1–17.
   Google Scholar
• Panackal AA, Parisini E, Proschan M. Salvage combination antifungal therapy for acute invasive aspergillosis may improve outcomes: a systematic review and meta-analysis. Int J Infect Dis. 2014;28:80–94. doi:10.1016/j.ijid.2014.07.007
   PubMed Web of Science ®Google Scholar
• Garnacho-Montero J, Olaechea P, Alvarez-Lerma F, et al. Epidemiology, diagnosis and treatment of fungal respiratory infections in the critically ill patient. Rev Esp Quimioter. 2013;26(2):173–188.
   PubMed Web of Science ®Google Scholar
• Blot S, Koulenti D, Dimopoulos G. Invasive Pulmonary  aspergillosis in Critically Ill Patients. Vincent J-L, editor. Berlin Heidelberg: Springer; 2013.
   Google Scholar
• Ibrahim AS, Gebremariam T, Fu Y, Edwards JE Jr., Spellberg B. Combination echinocandin-polyene treatment of murine mucormycosis. Antimicrob Agents Chemother. 2008;52(4):1556–1558. doi:10.1128/AAC.01458-07
   PubMed Web of Science ®Google Scholar
• Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bioavailability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol. 2004;57(2):218–222. doi:10.1046/j.1365-2125.2003.01977.x
   PubMed Web of Science ®Google Scholar
• Chen L, Krekels EHJ, Verweij PE, Buil JB, Knibbe CAJ, Brüggemann RJM. Pharmacokinetics and pharmacodynamics of posaconazole. Drugs. 2020;80(7):671–695. doi:10.1007/s40265-020-01306-y
   PubMed Web of Science ®Google Scholar
• Li Y, Theuretzbacher U, Clancy CJ, Nguyen MH, Derendorf H. Pharmacokinetic/pharmacodynamic profile of posaconazole. Clin Pharmacokinet. 2010;49(6):379–396. doi:10.2165/11319340-000000000-00000
   PubMed Web of Science ®Google Scholar
• Barde F, Billaud E, Goldwirt L, et al. Low central nervous system posaconazole concentrations during cerebral phaeohyphomycosis. Antimicrob Agents Chemother. 2019;63:11. doi:10.1128/AAC.01184-19
   Web of Science ®Google Scholar
• Hoenigl M, Krause R. Antifungal therapy of aspergillosis of the central nervous system and aspergillus endophthalmitis. Curr Pharm Des. 2012;2012:1.
   Google Scholar
• Durgun ME, Kahraman E, Hacıoğlu M, Güngör S, Özsoy Y. Posaconazole micelles for ocular delivery: in vitro permeation, ocular irritation and antifungal activity studies. Drug Deliv Transl Res. 2022;12(3):662–675. doi:10.1007/s13346-021-00974-x
   PubMed Web of Science ®Google Scholar
• Lipp HP. Posaconazole: clinical pharmacokinetics and drug interactions. Mycoses. 2011;54(Suppl 1):32–38. doi:10.1111/j.1439-0507.2010.01984.x
   PubMed Web of Science ®Google Scholar
• Lepak AJ, Andes DR. Antifungal pharmacokinetics and pharmacodynamics. Cold Spring Harb Perspect Med. 2014;5(5):a019653. doi:10.1101/cshperspect.a019653
   PubMed Web of Science ®Google Scholar
• Lewis JS 2nd, Wiederhold NP, Hakki M, Thompson GR 3rd. New perspectives on antimicrobial agents: isavuconazole. Antimicrob Agents Chemother. 2022;66(9):e0017722. doi:10.1128/aac.00177-22
   PubMed Web of Science ®Google Scholar
• Schmitt-Hoffmann A, Desai A, Kowalski D, Pearlman H, Yamazaki T, Townsend R. Isavuconazole absorption following oral administration in healthy subjects is comparable to intravenous dosing, and is not affected by food, or drugs that alter stomach pH. Int J Clin Pharmacol Ther. 2016;54(8):572–580. doi:10.5414/CP202434
   PubMed Web of Science ®Google Scholar
• Desai A, Schmitt-Hoffmann AH, Mujais S, Townsend R. Population pharmacokinetics of isavuconazole in subjects with mild or moderate hepatic impairment. Antimicrob Agents Chemother. 2016;60(5):3025–3031. doi:10.1128/AAC.02942-15
   PubMed Web of Science ®Google Scholar
• Townsend RW, Akhtar S, Alcorn H, et al. Phase I trial to investigate the effect of renal impairment on isavuconazole pharmacokinetics. Eur J Clin Pharmacol. 2017;73(6):669–678. doi:10.1007/s00228-017-2213-7
   PubMed Web of Science ®Google Scholar
• Perfect JR, Cornely OA, Heep M, et al. Isavuconazole treatment for rare fungal diseases and for invasive aspergillosis in patients with renal impairment: challenges and lessons of the VITAL trial. Mycoses. 2018;61(7):420–429. doi:10.1111/myc.12769
   PubMed Web of Science ®Google Scholar
• Maertens JA, Rahav G, Lee DG, et al. Posaconazole versus voriconazole for primary treatment of invasive aspergillosis: a Phase 3, randomised, controlled, non-inferiority trial. Lancet. 2021;397(10273):499–509. doi:10.1016/S0140-6736(21)00219-1
   PubMed Web of Science ®Google Scholar
• Maertens JA, Kontoyiannis DP, Cornely OA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769. doi:10.1016/S0140-6736(15)01159-9
   PubMed Web of Science ®Google Scholar
• Tissot F, Agrawal S, Pagano L, et al. ECIL-6 guidelines for the treatment of invasive candidiasis, aspergillosis and mucormycosis in leukemia and hematopoietic stem cell transplant patients. Haematologica. 2017;102(3):433–444. doi:10.3324/haematol.2016.152900
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Aguado JM, Arikan-Akdagli S, et al. Diagnosis and management of aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clin Microbiol Infect. 2018;24(Suppl 1):e1–e38. doi:10.1016/j.cmi.2018.01.002
   PubMed Web of Science ®Google Scholar
• Heldt S, Prattes J, Eigl S, et al. Diagnosis of invasive aspergillosis in hematological malignancy patients: performance of cytokines, Asp LFD, and aspergillus PCR in same day blood and bronchoalveolar lavage samples. J Infect. 2018;77(3):235–241. doi:10.1016/j.jinf.2018.05.001
   PubMed Web of Science ®Google Scholar
• Eigl S, Hoenigl M, Spiess B, et al. Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis. Med Mycol. 2017;55(5):528–534. doi:10.1093/mmy/myw102
   PubMed Web of Science ®Google Scholar
• Eigl S, Prattes J, Reinwald M, et al. Influence of mould-active antifungal treatment on the performance of the Aspergillus-specific bronchoalveolar lavage fluid lateral-flow device test. Int J Antimicrob Agents. 2015;46(4):401–405. doi:10.1016/j.ijantimicag.2015.05.017
   PubMed Web of Science ®Google Scholar
• Egger M, Jenks JD, Hoenigl M, Prattes J. Blood aspergillus PCR: the good, the bad, and the ugly. J Fungi. 2020;6(1):E18. doi:10.3390/jof6010018
   Web of Science ®Google Scholar
• Hoenigl M, Orasch T, Faserl K, et al. Triacetylfusarinine C: a urine biomarker for diagnosis of invasive aspergillosis. J Infect. 2018;2018:1.
   Google Scholar
• Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408–415. doi:10.1056/NEJMoa020191
   PubMed Web of Science ®Google Scholar
• Salmanton-García J, Au WY, Hoenigl M, et al. The current state of laboratory mycology in Asia/Pacific: a survey from the European Confederation of Medical Mycology (ECMM) and International Society for Human and Animal Mycology (ISHAM). Int J Antimicrob Agents. 2023;61:106718. doi:10.1016/j.ijantimicag.2023.106718
   PubMed Web of Science ®Google Scholar
• Driemeyer C, Falci DR, Oladele RO, et al. The current state of clinical mycology in Africa: a European confederation of medical mycology and international society for human and animal mycology survey. Lancet Microb. 2022;3(6):e464–e470. doi:10.1016/S2666-5247(21)00190-7
   PubMedGoogle Scholar
• Rudramurthy SM, Hoenigl M, Meis JF, et al. ECMM/ISHAM recommendations for clinical management of COVID −19 associated mucormycosis in low- and middle-income countries. Mycoses. 2021;64:1028–1037. doi:10.1111/myc.13335
   PubMed Web of Science ®Google Scholar
• Gebremariam T, Gu Y, Alkhazraji S, Youssef E, Shaw KJ, Ibrahim AS. The combination treatment of fosmanogepix and liposomal amphotericin B is superior to monotherapy in treating experimental invasive mold infections. Antimicrob Agents Chemother. 2022;66(7):e0038022. doi:10.1128/aac.00380-22
   PubMed Web of Science ®Google Scholar
• Pappas PKB, Kullberg BJ, Vazquez JA, et al. 147. clinical safety and efficacy of novel antifungal, fosmanogepix, in the treatment of candidemia: results from a phase 2 proof of concept trial. Open Forum Infect Dis. 2020;7(Supplement_1):S203–S204. doi:10.1093/ofid/ofaa439.457
   Google Scholar
• Georgacopoulos O, Nunnally NS, Ransom EM, et al. In vitro activity of novel antifungal olorofim against filamentous fungi and comparison to eight other antifungal agents. J Fungi. 2021;7(5):378. doi:10.3390/jof7050378
   Web of Science ®Google Scholar
• Rivero-Menendez O, Soto-Debran JC, Cuenca-Estrella M, Alastruey-Izquierdo A. In vitro activity of ibrexafungerp against a collection of clinical isolates of aspergillus, including cryptic species and Cyp51A mutants, using EUCAST and CLSI methodologies. J Fungi. 2021;7:3. doi:10.3390/jof7030232
   Web of Science ®Google Scholar
• Colley T, Sehra G, Daly L, et al. Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory aspergillus fumigatus infection. Sci Rep. 2019;9(1):9482. doi:10.1038/s41598-019-45890-w
   PubMedGoogle Scholar
• Sandison T, Ong V, Lee J, Thye D. Safety and pharmacokinetics of CD101 IV, a novel echinocandin, in healthy adults. Antimicrob Agents Chemother. 2017;61(2). doi:10.1128/AAC.01627-16
   Web of Science ®Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837. doi:10.1016/S1473-3099(16)00071-2
   PubMed Web of Science ®Google Scholar
• Salmanton-García J, Seidel D, Koehler P, et al. Matched-paired analysis of patients treated for invasive mucormycosis: standard treatment versus posaconazole new formulations (MoveOn). J Antimicrob Chemother. 2019;74(11):3315–3327. doi:10.1093/jac/dkz344
   PubMed Web of Science ®Google Scholar
• Armstrong-James D, Koh M, Ostermann M, Cockwell P. Optimal management of acute kidney injury in critically ill patients with invasive fungal infections being treated with liposomal amphotericin B. BMJ Case Rep. 2020;13(5):e233072. doi:10.1136/bcr-2019-233072
   PubMedGoogle Scholar
• Hoenigl M, Lewis R, van de Veerdonk FL, Verweij PE, Cornely OA. Liposomal amphotericin B-the future. J Antimicrob Chemother. 2022;77(Suppl_2):ii21–ii34. doi:10.1093/jac/dkac353
   PubMedGoogle Scholar
• Gebremariam T, Gu Y, Singh S, Kitt TM, Ibrahim AS. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis. J Antimicrob Chemother. 2021;76(10):2636–2639. doi:10.1093/jac/dkab233
   PubMed Web of Science ®Google Scholar
• Miller MA, Molina KC, Gutman JA, et al. Mucormycosis in hematopoietic cell transplant recipients and in patients with hematological malignancies in the era of new antifungal agents. Open Forum Infect Dis. 2021;8(2):ofaa646. doi:10.1093/ofid/ofaa646
   PubMed Web of Science ®Google Scholar
• Jenks JD, Mehta SR, Hoenigl M. Broad spectrum triazoles for invasive mould infections in adults: which drug and when? Med Mycol. 2019;57(Supplement_2):S168–s78. doi:10.1093/mmy/myy052
   PubMedGoogle Scholar
• Jenks JD, Salzer HJ, Prattes J, Krause R, Buchheidt D, Hoenigl M. Spotlight on isavuconazole in the treatment of invasive aspergillosis and mucormycosis: design, development, and place in therapy. Drug Des Devel Ther. 2018;12:1033–1044. doi:10.2147/DDDT.S145545
   PubMed Web of Science ®Google Scholar
• Gebremariam T, Alkhazraji S, Gu Y, et al. 726. APX001 (Fosmanogepix) is effective in an immunosuppressed mouse model of rhizopus oryzae infection. Open Forum Infect Dis. 2019;6(Supplement_2):S325–S6. doi:10.1093/ofid/ofz360.794
   Google Scholar
• Gebremariam T, Alkhazraji S, Alqarihi A, et al. Fosmanogepix (APX001) is effective in the treatment of pulmonary murine mucormycosis due to rhizopus arrhizus. Antimicrob Agents Chemother. 2020;64(6). doi:10.1128/AAC.00178-20
   Web of Science ®Google Scholar
• Angulo DA, Alexander B, Rautemaa-Richardson R, et al. Ibrexafungerp, a novel triterpenoid antifungal in development for the treatment of mold infections. J Fungi. 2022;8(11):51.
   Web of Science ®Google Scholar
• Teklegiorgis GSA, Yiyou G, Ibrahim A. Ibrexafungerp Is effective in treating murine mucormycosis caused by Rhizopus delemar. Trend Med Mycol. 2021;2021:1.
   Google Scholar
• Hoenigl M, Egger M, Price J, Krause R, Prattes J, White PL. Metagenomic next-generation sequencing of plasma for diagnosis of COVID-19-associated pulmonary aspergillosis. J Clin Microbiol. 2023;1(1):e01859–22.
   Google Scholar
• Hoenigl M, Salmanton-García J, Egger M, et al. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study. Lancet Infect Dis. 2023. doi:10.1016/S1473-3099(22)00872-6
   PubMed Web of Science ®Google Scholar
• Verweij PE, Chowdhary A, Melchers WJ, Meis JF. Azole resistance in aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles? Clin Infect Dis. 2016;62(3):362–368. doi:10.1093/cid/civ885
   PubMed Web of Science ®Google Scholar